Abstract:Platelets play a significant role in hemostasis, forming plugs at sites of vascular injury to limit blood loss. However, if platelet activation is not controlled, it can lead to thrombotic events, such as myocardial infarction and stroke. To prevent this, antiplatelet agents are used in clinical settings to limit platelet activation in patients at risk of arterial thrombotic events. However, their use can be associated with a significant risk of bleeding. An enhanced comprehension of platelet signaling mechanisms should facilitate the identification of safer targets for antiplatelet therapy. Over the past decade, our comprehension of the breadth and intricacy of signaling pathways that orchestrate platelet activation has expanded exponentially. Several recent studies have provided further insight into the regulation of platelet signaling events and identified novel targets against which to develop novel antiplatelet agents. Antiplatelet drugs are essential in managing atherothrombotic vascular disease. The current antiplatelet therapy in clinical practice is limited in terms of safety and efficacy. Novel compounds have been developed in response to patient variability and resistance to aspirin and/or clopidogrel. Recent studies based on randomized controlled trials and systematic reviews have definitively demonstrated the role of antiplatelet therapy in reducing the risk of cardiovascular events. Antiplatelet therapy is the recommended course of action for patients with established atherosclerosis. These studies compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention. However, in patients undergoing percutaneous coronary intervention, it is still unclear whether the efficacy of P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy depends on the type of P2Y12 inhibitor. This paper focuses on the advanced-stage evaluation of several promising antiplatelet drugs.

Advances of Antiplatelet Therapies

Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic

The Application of Triple Antithrombotic Therapy Combined with Aspirin,Clopidogrel and Warfarin in Patients with Coronary Heart Disease

2018 Update of Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI

Review ontheEffect of Tea on PlateletActivation

Current status and progress of percutaneous coronary intervention-related platelet P2Y12 receptor blockers

Progress of novel oral antiplatelet medicine in acute coronary syndrome

Developments in Inhibiting Platelet Aggregation Based on Different Design Strategies

Clinical pharmacology of antiplatelet drugs

Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

Research progress of antiplatelet drug "nonresponder"

Current situation of platelet function tests and their clinical application status during antiplatelet treatment

Current concepts and novel targets for antiplatelet therapy

Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents

Drug Resistance and Strategies in Antiplatelet Therapy for the Management of Ischemic Stroke

Application of Clopidogrel in the Treatment of Coronary Artery Disease

P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application

The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic stroke

Advances in antithrombotic therapy of atrial fibrillation complicated with coronary artery disease

Research progress on the application of aspirin and its derivatives in the treatment and rehabilitation of cardiovascular diseases